GZMA and leishmaniasis: Considering the expression of cytotoxic biomarkers, including granzymes A /B and chemokine CXCL10 in CL, it is possible to use the approach of designing agonists to make potential vaccines, as well as the strategy of considering antagonists to design drugs to modulate immune responses in leishmaniasis.